Parking (from CAT website) -
CAT's patent portfolio includes about 30 families of patents, covering both technologies and products. CAT's core phage display technology is covered by three main families of patents:
* 'Winter II' covers CAT's processes for generating the collections of antibody genes that comprise CAT's libraries. CAT has patents issued in Europe, South Korea, Japan and Australia, which expire in 2009. Patent applications are pending in the USA and Canada. The Winter II patent is co-owned by the MRC, the Scripps Research Institute and Stratagene and CAT has exclusive commercial exploitation rights, subject to certain rights held by the Medical Research Council (MRC), Scripps and Stratagene and their pre-existing licensees.
* 'McCafferty' covers the process by which antibodies are displayed on phage (phage display) and methods of selecting antibodies to desired targets from libraries. CAT has patents issued in Europe, Australia and South Korea, which expire in 2011, and two patents in the USA, which expire in 2016. CAT currently has patent applications pending in Canada and Japan, and has made divisional applications in Europe. These patents are co-owned by CAT and the MRC.
* 'Griffiths' covers the use of phage display technology to isolate human 'anti-self' antibodies that bind to molecules found in the human body. CAT has a patent issued in Australia, which expires in 2012, and the USA, which expires in 2016. CAT has patent applications pending in Canada, Europe and Japan, which, if granted, would expire in 2012. This patent is co-owned by CAT and the MRC.
Other patents that cover CAT's technology include those that cover ProxiMol® and ribosome display (purchased from Aptein).
Patents are also in place to protect the products that CAT is developing.
Patent disputes are relatively common in biotechnology as compared with other fields and some of CAT's patents are the subject of dispute. However, CAT believes that whatever the outcome of current litigation activity, its ability to operate its own technology will not be materially and adversely affected.
For detailed information on CAT's patents, follow the links below. These are direct links to the abstract and details, but may take some time to download.
Winter II
delphion.com
Winter II (Europe)
delphion.com
McCafferty
delphion.com
McCafferty (Europe)
delphion.com
McCafferty (US)
delphion.com
Griffiths
delphion.com
Griffiths (US)
delphion.com
ProxiMol
delphion.com
Ribosome display
delphion.com |
